News coverage about Chromadex (NASDAQ:CDXC) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chromadex earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.1430199925784 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Risk Factors under Consideration – ChromaDex Corporation … – Stock Watch (stocksnewstimes.com)
- Stock’s Technical Levels Evaluation – ChromaDex Corporation (NASDAQ: CDXC) – Stocks Pen (stockspen.com)
- Head-To-Head Comparison: Anthera Pharmaceuticals (ANTH) & Chromadex (CDXC) (americanbankingnews.com)
- Stock’s Technical Levels under Review – ChromaDex Corporation (NASDAQ: CDXC) – The Investor Guide (wallstreetnews24.com)
- Chromadex (CDXC) Given a $8.00 Price Target at HC Wainwright (americanbankingnews.com)
CDXC stock traded up $0.08 during trading on Wednesday, hitting $5.05. The company’s stock had a trading volume of 210,337 shares, compared to its average volume of 499,692. The company has a market cap of $276.92, a P/E ratio of -20.20 and a beta of 0.82. Chromadex has a 1-year low of $2.26 and a 1-year high of $7.24. The company has a current ratio of 7.08, a quick ratio of 6.36 and a debt-to-equity ratio of 0.01.
CDXC has been the subject of a number of recent research reports. HC Wainwright set a $8.00 price target on Chromadex and gave the company a “buy” rating in a research note on Friday, February 9th. BidaskClub downgraded Chromadex from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, Zacks Investment Research upgraded Chromadex from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research note on Tuesday, November 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Chromadex has a consensus rating of “Hold” and an average price target of $7.50.
In related news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $6.52, for a total transaction of $185,031.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $6.19, for a total value of $361,496.00. The disclosure for this sale can be found here. Insiders own 11.59% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Chromadex (NASDAQ:CDXC) Receiving Somewhat Positive Media Coverage, Analysis Finds” was first published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/21/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-chromadex-cdxc-stock-price/1923645.html.
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.